NCRN Lymphoma Cancer Studies Open to Recruitment

 
Please note the portfolio will be updated on a monthly basis and includes open studies only. If you have any queries please contact the NISCHR CRC Information and Portfolio team portfolio@wales.nhs.uk          
 
An asterisk denotes that the study is open in at least one site in that region. 
 
  

Study Name

Study Description

North Wales

South East Wales

South West Wales

NCRN173-GADOLIN:Bendamustine + GA101 in  Rituximab refractory, indolent NHL

An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximabrefractory, indolent NonHodgkin's Lymphoma

 

 

*

NCRN316 MABCUTE - Rixutimab in non-Hodgkin's lymphoma

A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.

 

*

 

NCRN414 LUMIERE - Alisertib vs in relapsed or refractory peripheral T-cell lymphoma

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

 

*

 

NCRN481: MABEASE SC vs IV rituximab + CHOP in untreated DLBCL

A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV)  RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

 

 

*

NCRN487: A+AVD vs ABVD in first line advanced Hodgkin Lymphoma A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

 

*

NCRN579 - PCI-32765 vs. Chlorambucil in Treatmentnaive CLL or SLL

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatmentnaive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

 

*

 
PACIFICO

Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym:  RiCH FLO)

*

*

 

REMoDLB

A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib

*

*

 

TRYMS Testosterone Replacement in Young Male cancer Survivors  

*

 

UKALL 2011

United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011

 

*

 

 

 
 
Hospitals supported by the WCRN Research Networks:
 
 
North Wales Hospitals South East Wales Hospitals South West Wales Hospitals
Glan Clwyd, Rhyl Llandough Bronglais
Wrexham Maelor Nevill Hall Morriston
Ysbyty Gwynedd, Bangor Prince Charles
Neath Port Talbot
  Princess of Wales   Prince Phillip
  Royal Glamorgan  Singleton
  Royal Gwent and St Woolos West Wales General
  University Hospital of Wales
Withybush
  Velindre Cancer Centre  
  
 


Last updated: 28/03/2014